Julie Ryan Wolf, PhD, MPH
Corina van den Hurk, PhD
The Netherlands

>> How to Join
To join a Study Group, login to your account, and click the Manage My Account/Profile.  Scroll down to your profile data and select "Edit". Then select the study group as one of your three Study Group selections. Click SAVE.

To join a Subgroup, you must be a member of the parent Study Group. Login to your account, and click Manage My Account/Profile.  Scroll down to your profile data and select "Edit". Then select the subgroup. Click SAVE.
Subgroups do not count toward your three Study Group selections.
>> More information or to contact Study Group/Subgroup leadership
To contact a Study Group or Subgroup Leader, search for their name in the member directory.
For more information or questions, contact the MASCC office at [email protected].

Mission and Goals

The mission of the MASCC Oncodermatology Study Group is to develop research and management strategies for skin conditions due to cancer or anticancer drugs. Skin reactions are frequent in those affected by cancer. They can reduce quality of life and require modifications in lifesaving antineoplastic therapy. This interdisciplinary Study Group aims to raise awareness of dermatological conditions in cancer patients and take a leadership role in the emerging field of cancer-related skin toxicities management.

The objectives of the Oncodermatology Study Group include the following:

  • To identify new targets for the treatment of skin reactions
  • To establish guidelines for management
  • To contribute to patients' knowledge of reactions and their care

Key efforts are directed toward the identification of phenotypes and treatment regimens with a higher risk, as well as preventive measures and early intervention as standards of care. This Study Group also serves as a resource for multi-center clinical trials and translational studies.

Study Group Activities
Tools & Apps
Patient Education
Study Group News
Study Group Annual Report


Last Updated on Tuesday, October 12, 2021 09:58 AM